Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis
Title:
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis
Author:
Lampertico, P. Soffredini, R. Yurdaydin, C. Idilman, R. Papatheodoridis, G.V. Margariti, A. Buti, M. Esteban, R. Zaltron, S. Vavassori, A. Castelli, F. Viganò, M. Rumi, M.G. Vinci, M. Belli, L.S. Cologni, G. Rizzi, M. Milanese, M. Strazzabosco, M. Minola, E. Giorgini, A.M. Zuin, M. Salmi, A. Colombo, S. Fracassetti, O. Del Poggio, P. Bruno, S. Pasulo, L. Fagiuoli, S. Andreoletti, M. Colli, A. Colombo, A.E. Bellati, G. Magni, C. Angeli, E. Gubertini, G.A. Rizzardini, G. Fasano, M. Santantonio, T. Terreni, N.M. Spinzi, G. Facchetti, F. Invernizzi, F. Mangia, G. Colombo, M.